Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KDM6A | O15550 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684099 | 0.84 | TSHR (0.54) | ALDH1A1POLBTSHRLMNAPTGS2 | |
| SCHEMBL28911890 | 0.75 | MAOB (0.53) | SMN1; SMN2MAOB | |
| SCHEMBL1520258 | 0.63 | TSHR (1.00) | ALDH1A1CYP2C19CYP2C9POLBSMN1; SMN2 | |
| SCHEMBL6238748 | 0.63 | ALDH1A1 (0.67) | ALDH1A1CYP2C19SMN1; SMN2TSHRKDM4E | |
| SCHEMBL16642162 | 0.63 | ALDH1A1 (0.67) | ALDH1A1CYP2C19SMN1; SMN2TSHRKDM4E | |
| SCHEMBL112540 | 0.63 | ALDH1A1 (0.67) | ALDH1A1CYP2C19SMN1; SMN2TSHRKDM4E | |
| SCHEMBL1423877 | 0.62 | SMN1; SMN2 (0.67) | ALDH1A1CYP2C19POLBSMN1; SMN2LMNA | |
| SCHEMBL27862919 | 0.62 | ALDH1A1 (0.59) | ALDH1A1CYP2C19TSHRLMNAKDM4E | |
| SCHEMBL2992964 | 0.62 | ALDH1A1 (1.00) | ALDH1A1CYP2C19POLBSMN1; SMN2LMNA | |
| SCHEMBL2004792 | 0.62 | ALDH1A1 (0.73) | ALDH1A1CYP2C19SMN1; SMN2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474396-B9 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1474396-B1 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1474396-A4 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6932960-B2 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-6825204-B2 | FOR THERAPY OF DISEASES, SUCH AS PARASITIC AND VIRAL INFECTIONS, CONDITIONS ASSOCIATED WITH INFLAMMATION AND INFECTION, AND CONDITIONS MEDIATED BY CELL-PROLIFERATION OR COLLAGEN FORMATION; CONTRAST AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1474396-A2 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040176326-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20030170174-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003065991-A2 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176326-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | COL1A1, CD4, COL2A1 | ALDH1A1 1505/4885CYP2C19 200/4885CYP2C9 467/4885 |
| US-20030170174-A1 | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof | COL1A1, CD4, COL2A1 | ALDH1A1 1505/4885CYP2C19 200/4885CYP2C9 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.